WorldPharmaNews
  • Home
  • Business
  • Research
  • Jobs
  • Events
  • Regulatory

Pfizer

PfizerAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.

www.pfizer.com

Filters
List of articles in category Pfizer
Title Published Date
Pfizer celebrates a year of achievements in 2015 annual review 16 March 2016
Pfizer commences $5 billion accelerated share repurchase 11 March 2016
Merck, Pfizer and Verastem announce combination trial of avelumab and VS-6063 in ovarian cancer 04 March 2016
Pfizer names executive leadership team for combined organization upon close of proposed Allergan transaction 08 February 2016
Bristol-Myers Squibb and Pfizer sign collaboration with Portola Pharmaceuticals 02 February 2016
Pfizer expands R&D equity investment strategy to access early-stage scientific innovations 13 January 2016
Merck KGaA, Darmstadt, Germany, Pfizer and Syndax announce collaboration to evaluate combination of Avelumab and Entinostat in ovarian cancer 04 January 2016
Global partners announce donation of 500 millionth dose of azithromycin 17 November 2015
Pfizer expands its patient assistance program 10 November 2015
Pfizer completes acquisition of Nimenrix and Mencevax from GlaxoSmithKline 06 October 2015
New Centrum® VitaMints® offer a refreshingly new way to take a multivitamin 24 September 2015
Pfizer and Synthon enter into U.S. commercialization agreement for potential generic treatment of multiple sclerosis 04 August 2015
Pfizer's Centers for Therapeutic Innovation and Jeffrey Modell Foundation announce collaboration 13 July 2015
Pfizer enters into agreement to acquire Nimenrix and Mencevax from GlaxoSmithKline 23 June 2015
Get Ready. Get Set. Get Old. 04 June 2015
Pfizer announces $3 million grants program to further clinical research in advanced breast cancer 28 May 2015
Pfizer acquires minority interest in AM-Pharma; secures option to acquire company 11 May 2015
Pfizer and Lilly preparing to resume Phase 3 chronic pain program for Tanezumab 23 March 2015
Pfizer to Acquire Hospira 06 February 2015
Acquisition provides Pfizer with a preclinical CMV vaccine candidate 09 January 2015
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • End

Business & Industry

  • Trastuzumab deruxtecan achieved a tumour response rate of 60.9% in pivotal Phase II HER2-positive metastatic breast cancer trial
  • Novartis expects to sustain long-term growth with a robust pipeline of 25+ potential blockbusters
  • Roche and Spark Therapeutics, Inc. announce extension of tender offer
  • AWS announces strategic collaboration with Novartis to accelerate digital transformation of its business operations
  • AstraZeneca divests rights to Seroquel and Seroquel XR in the US and Canada

Research & Development

  • A vaccine against chronic inflammatory diseases
  • Microcapsules for targeted drug delivery to cancer cells
  • Leukemia, lymphoma squarely in sights of new class of drugs
  • First investigational drug therapy for liver disease NASH awaiting FDA approval
  • The gut may be involved in the development of multiple sclerosis
  • Olaparib becomes first gene-targeted medicine to show benefits in prostate cancer
  • Investigational drugs reduce risk of death from Ebola virus disease

Conferences & Events

  • Excellent market conditions at largest ever CPhI Worldwide bodes well for global pharma in 2020
  • SMi Group's 12th Annual Conference and Exhibition: Pre-Filled Syringes and Injectable Drug Devices 2020
  • SMi's 4th Annual 3D Cell Culture
  • Exploring the dynamics, legalities and hurdles in a period of transition for Parallel Trade
  • RNA Therapeutics Conference and Focus Day
  • CPhI Worldwide announces the winners of the 16th Pharma Awards
  • CPhI Annual Report predicts Europe to surpass the USA in biologic manufacturing capacity by 2023

Regulatory Affairs

  • FDA launches app for health care professionals
  • FDA approves first generics of Gilenya
  • FDA approves novel treatment to target abnormality in sickle cell disease
  • FDA approves first treatment for inherited rare disease
  • FDA approves first targeted therapy to treat patients with painful complication of sickle cell disease
  1. You are here:  
  2. Home
  3. Pfizer
  4. U.S. Food And Drug Administration Approves Pfizer's XALKORI® (crizotinib)

About

  • Home
  • Advertise
  • Privacy
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • Google+
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2006 - 2017. All Rights Reserved. WORLD PHARMA JOBS | PharmaNews.eu | eHealthNews.eu | (HEALTH IT) SPACE